Streaming issues? Report here
money-show-thumbnailjpg money-show-thumbnailjpg
The Money Show with Bruce Whitfield
18:00 - 20:00
volume_up
volume_mute

Up Next: Tonight with Lester Kiewit
See full line-up
The Money Show with Bruce Whitfield
18:00 - 20:00

Podcasts

The Money Show with Bruce Whitfield
arrow_forward
Sales at Spar’s Tops stores skyrocket 19.3% despite the weak economy

Sales at Spar’s Tops stores skyrocket 19.3% despite the weak economy

15 May 2019 6:52 PM

Despite the economy, or because of it? The Money Show's Bruce Whitfield interviews Graham O'Connor, Spar Group CEO.


More episodes from The Best of the Money Show

Market Commentary

2 July 2020 6:37 PM

Guest: Graeme Korner/ at Korner Perspective 

LISTEN TO PODCAST arrow_forward

Meat imposters say Fairplay's dumping concerns is just a Covid blame game

2 July 2020 6:36 PM

Guest: Paul Matthew/ CEO at Association of Meat Importers and Exporters 

LISTEN TO PODCAST arrow_forward

Four unions sign up for voluntary SAA severance packages

2 July 2020 6:22 PM

Guest: Kgathatso Tlhakudi/ Acting Director General at Department of Public Enterprises 

LISTEN TO PODCAST arrow_forward

Shapeshifter - SA Animation company triggerfish now in Ireland

1 July 2020 8:09 PM

Guest: Stuart Forrest/ CEO at Triggerfish 

LISTEN TO PODCAST arrow_forward

Drug profits - a neccessary evil or something that needs to change

1 July 2020 7:25 PM

Using profit to solve health issues does not work in a pandemic, perhaps at all.

This is a really complex issue. How should we fund the research for more effective drugs to treat conditions that may affect millions, knowing that many will not work and then determine how to price those that do work to cover the costs not just of the drug that did work, but the research for those that did not.

The cost to produce the drug has components that include the search for the potential candidates, the development of the tests on animals and then humans and the ongoing monitoring to determine its effect.

The mechanism to do this has been to have for profit companies get patents for their discoveries and then get a period between 5, 12 and sometimes over 20 years to be able to exclusively supply the drug and set its price.

There is no question that the system can be better. The question is how and despite many attempts by those that have practical alternatives, it does not appear enough has changed to make medicine more accessible.

Could the Covid-19 pandemic provide the public support to overcome the financial resistance that those that benefit from the status quo?

Image credit - Pexels

LISTEN TO PODCAST arrow_forward

Real Food's Kauai is not chicken about expansion

1 July 2020 6:55 PM

Guest: Dean Kowarski/ CEO at Real Foods Group 

LISTEN TO PODCAST arrow_forward

Market Commentary

1 July 2020 6:36 PM

Guest: Chris Steward/ Portfolio Manager at Ninety One 

LISTEN TO PODCAST arrow_forward

Landlords are operating as property cartels- Mid sized independent retailers

1 July 2020 6:35 PM

Guest: Jonathan Kingsley- Hall/ Fpunder at JKH  Business and property Consulting 

LISTEN TO PODCAST arrow_forward